Expand KYMR Menu
KYMR MENU

KYMR Latest Press Releases

-- September 2, 2026 --

Kymera Therapeutics to Participate in Upcoming September Investor Conferences Globe Newswire 4:01 PM

-- September 1, 2026 --

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses Globe Newswire 7:00 AM

-- August 5, 2026 --

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update Globe Newswire 7:00 AM

-- July 28, 2026 --

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026 Globe Newswire 4:01 PM

-- July 27, 2026 --

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer Globe Newswire 4:01 PM
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm PRNewswire 8:49 AM

-- July 17, 2026 --

Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm Globe Newswire 4:21 PM

-- July 16, 2026 --

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PRNewswire 11:13 AM

-- July 7, 2026 --

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader Globe Newswire 7:00 AM

-- June 25, 2026 --

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 Globe Newswire 7:00 AM

-- June 24, 2026 --

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors Globe Newswire 4:01 PM

-- June 12, 2026 --

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting Globe Newswire 7:00 AM

-- June 9, 2026 --

Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration Globe Newswire 7:00 AM

-- June 8, 2026 --

Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations Globe Newswire 4:01 PM
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses Globe Newswire 7:00 AM

-- May 27, 2026 --

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference Globe Newswire 7:00 AM

-- May 15, 2026 --

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses Globe Newswire 7:00 AM

-- May 12, 2026 --

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PRNewswire 10:00 AM

-- May 6, 2026 --

Kymera Therapeutics to Participate in Upcoming May Investor Conferences Globe Newswire 7:00 AM

-- May 5, 2026 --

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week Globe Newswire 7:00 AM
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent Business Wire 6:37 AM

-- April 30, 2026 --

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update Globe Newswire 7:00 AM
Market Data Delayed 15 Minutes